Neue „Targets” und Substanzen zur medikamentösen Therapie des fortgeschrittenen Nierenzellkarzinoms

Zusammenfassung

Die Ergebnisse der Immuntherapien zur Behandlung des fortgeschrittenen Nierenzellkarzinoms sind hinter den initialen Erwartungen zurückgeblieben. Neue, vielversprechende Substanzen, die breitflächig in die Onkologie Einzug gefunden haben, zeigen auch am Nierenkarzinom erste, zum Teil sehr ermutigende Therapieerfolge. Hierzu zählen Antikörper oder (Rezeptor-)Tyrosin-Kinase-Inhibitoren, die allein oder in Kombination gegen die Aktivierung von Wachstumsfaktor-Rezeptoren (auf Gefäßendothel- und Tumorzellen) gerichtet sind. Die Behandlungsstrategien sind anti-angiogenetisch und anti-proliferativ ausgerichtet, und stehen vor der Marktreife.

Abstract

Conventional immunotherapeutic approaches have failed to achieve fundamental benefits for clinical outcome of patients with advanced metastatic renal cell carcinoma (MRCC). New, encouraging substances have gained broad access to the field of oncology and have already shown most promising preliminary results in patients with MRCC. Of mayor interest are antibodies and (receptor) tyrosine kinase inhibitors that are targeted against growth-factor receptors (of vascular endothelial and/or tumor cells). Single or multi-drug regimens are under way and are soon to be marketed.

Schlüsselwörter

Nierenzellkarzinom - fortgeschrittene, systemische Behandlung - Antikörpertherapie - Tyrosinkinase-Inhibitoren - Wachstumsfaktoren - Multi-Targeted-Drugs

Key words

Renal cell carcinoma - advanced, systemic therapy - immunotherapy - tyrosine kinase inhibitors - growth factors - multi-targeted strategies

Literatur

• 1 Ahmad T, Eisen T. Kinase inhibition with BAY 43-9006 in renal cell carcinoma.  Clin Cancer Res. 2004 Sep 15;  10 (18 Pt 2) 6388S-6392S
• 2 Castillo M, Petit A, Mellado B, Palacin A, Alcover J B, Mallofre C. C-kit expression in sarcomatoid renal cell carcinoma: potential therapy with imatinib.  J Urol. 2004;  171 2176-2180
• 3 Coppin C, Porzsolt F, Awa A, Kumpf J, Coldman A, Wilt T. Immunotherapy for advanced renal cell cancer.  Cochrane Database Syst Rev. 2005 Jan;  25 (1) CD001425
• 4 Dawson N A, Guo C, Zak R, Dorsey B, Smoot J, Wong J, Hussain A. A phase II trial of gefitinib (Fressa, ZD1839) in stage IV and recurrent renal cell carcinoma.  Clin Cancer Res. 2004;  10 7812-7819
• 5 Drucker B, Bacik J, Ginsberg M, Marion S, Russo P, Mazumdar M, Motzer R. Phase II trial of ZD1839 (IRESSA) in patients with advanced renal cell carcinoma.  Invest New Drugs. 2003;  21 341-345
• 6 George D, Michaelson D, Oh W K, Reitsma D, Laurent D, Mietlowski W, Wang Y, Dugan M, Kaelin W G, Kantoff P. Phase I study of PTK787/ZK 222584 (PTK/ZK) in metastatic renal cell carcinoma.  Proc Am Soc Clin Oncol. 2003;  22 385-(abstr 1548)
• 7 Hainsworth J D, Sosman J A, Spigel D R, Schwert R C, Carrell D L, Hubbard F, Greco F A. Phase II trial of bevacizumab and erlotinib in patients with metastastic renal carcinoma (RCC).  Journal of Clinical Oncology, ASCO Annual Meeting Proceedings (Post-Meeting Edition). 2004;  22, No 14S (July 15 Supplement) 4502
• 8 Herbst S R. A review of selected ASCO abstract Presentation on the annual ASCO-meeting 2004. 
• 9 Lynch T J, Bell D W, Sordella R, Gurubhagavatula S, Okimoto R A, Brannigan B W, Harris P L, Haserlat S M, Supko J G, Haluska F G, Louis D N, Christiani D C, Settleman J, Haber D A. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.  N Engl J Med. 2004;  350 2129-2139
• 10 Mendel D B, Laird A D, Xin X, Louie S G, Christensen J G, Li G, Schreck R E, Abrams T J, Ngai T J, Lee L B, Murray L J, Carver J, Chan E, Moss K G, Haznedar J O, Sukbuntherng J, Blake R A, Sun L, Tang C, Miller T, Shirazian S, McMahon G, Cherrington J M. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship.  Clin Cancer Res. 2003;  9 327-337
• 11 Motzer R J, Amato R, Todd M, Hwu W J, Cohen R, Baselga J, Muss H, Cooper M, Yu R, Ginsberg M S, Needle M. Phase II trial of antiepidermal growth factor receptor antibody C225 in patients with advanced renal cell carcinoma.  Invest New Drugs. 2003;  21 99-101
• 12 Motzer R J, Rini B I, Michaelson M D, Redman B G, Hudes G R, Wilding G, Figlin R A, Zhu J, Kim S T, Baum C. SU011248, a novel tyrosine kinase inhibitor, shows antitumor activity in second-line therapy for patients with metastatic renal cell carcinoma: Results of a phase II trial.  Journal of Clinical Oncology, 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition). 2004;  22, No 14S (July 15 Supplement) 4500
• 13 Ratain M J, Flaherty K T, Stadler W M, O'Dwyer P, Kaye S, Xiong H, Patnaik A, Gore M, Lee R J, Eisen T. Preliminary antitumor activity of BAY 43-9006 in metastatic renal cell carcinoma and other advanced refractory solid tumors in a phase II randomized discontinuation trial (RDT).  Journal of Clinical Oncology, ASCO Annual Meeting Proceedings (Post-Meeting Edition). 2004;  22, No 14S (July 15 Supplement) 4501
• 14 Sumitomo M, Asano T, Asakuma J, Asano T, Horiguchi A, Hayakawa M. ZD1839 modulates paclitaxel response in renal cancer by blocking paclitaxel-induced activation of the epidermal growth factor receptor-extracellular signal-regulated kinase pathway.  Clin Cancer Res. 2004;  10 794-801
• 15 Vuky J, Fotoohi M, Isacson C, Dela Cruz J, Otero H, Picozzi V, Aboulafia D, Malpass T, Jacobs A. Phase II trial of imatinib mesylate (formerly known as STI-571) in patients with metastatic renal cell carcinoma (RCC).  Proc Am Soc Clin Oncol. 2003;  22 416 (abstr 1672)